Eli Lilly is trading 7.29% up at $1,213.51 following its August 5 earnings report, driven by a significant increase in full-year revenue guidance and continued dominance in the GLP-1 market.
- Management raised 2026 revenue guidance to $85.0B–$87.0B, signaling robust long-term growth expectations.
- Tirzepatide products now account for 64% of total revenue, with additional momentum coming from progress on the company's oral weight-loss drug pipeline.